LATE MOVERS: Investors double down on Wynn Resorts after strong Macau revenue data; Lyft stock crashes after its blistering IPO

Also moving Monday were Lyft, drugmakers Merck and AstaZenica, and Brazilian financial tech company StoneCo

Wynn building
The casino resort chain led the Nasdaq and the S&P 500 on Monday

Wynn Resorts, Limited (NASDAQ:WYNN) shot up Monday after Harry Curtis of Instinet said that gross gaming revenue out of Macau, China fell less than expected. The resort casino chain brought in about 75% of its revenue from Macau in 2018, according to an SEC filing. Gross gaming revenue fell 0.4% in March, per MarketWatch, much less than the 3.2% analysts projected. As a result, Wynn was the biggest gainer on both the NASDAQ and the S&P 500.  

Investors were all-in, raising the share price 8.4% to close at $129.34.

Lyft Inc (NASDAQ:LYFT) stock fell back to Earth Monday after its red-hot IPO on Friday. The ride-sharing company set its IPO price at $72, and trading opened at $87.24, the biggest American IPO in five years. Now, the stock is down nearly $20 from its opening high. Meanwhile, Cboe Global Markets Inc (BATS:CBOE) announced it plans to list options on the San Francisco company’s stock on Thursday, per MarketWatch.

Investors made a U-turn, pushing the share price down nearly 12% to $69.01.

Kellogg Company (NYSE:K) stock slipped after the cereal maker announced Monday it would sell the Keebler cookie brand to Ferraro Group, the Italian company that owns Nutella, for $1.3 billion. Famous Amos brand cookies were also included in the sale, along with other brands of cookies, snacks, pie crusts and ice cream cones. In 2018, the brands being sold earned an operating profit of about $75 million on net sales of nearly $900 million.

The stock crumbled 2.4% to end at $56.02.

Merck & Co., Inc. (NSYEMRK) stock rose Monday after the drugmaker announced its cancer drug Keytruda was approved in China to treat non-small cell lung cancer in combination with chemotherapy. Keytruda is now the first Anti-PD-1 to be approved for multiple tumor types in China. The drug was approved for advanced melanoma in July.

The stock got a clean bill of health, climbing 0.2% to $83.30.

Merck was also working with AstraZenica PLC (NYSE:AZN) to co-develop MEK 1/2 inhibitor called Selumetinib that received a Breakthrough Therapy Designation in the US on Monday. The designation is for treatment of children with Neurofibromas Type 1, a genetic condition that causes tumors to grow along nerves. The UK drugmaker earned the designation based on promising Phase 2 data presented in 2018.

Shares jumped 2.1% to $41.28.

StoneCo Ltd (NASDAQ:STNE) rallied after the company announced Monday an additional public offering of its common stock along with preliminary first-quarter results. The Brazilian financial technology company is selling nearly 18 million shares but declined to specify a price. Meanwhile, the company expects to bring in total revenue between US$136.8 million and US$137.5 million compared with Street expectations of US$141 million and up from US$111.1 million the previous year.

The share price swung up 4.4% to finish at $42.93.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Euro Manganese prepares to file Environmental Assessment...

Euro Manganese (CVE: EMN- ASX: EMN) President and CEO Marco Romero joined Steve Darling from Proactive Vancouver with news the company is preparing the papers to file for an Environmental Impact Assessment on their project Chvaletice. Romero also told Proactive that they have initiated a...

21 minutes ago

3 min read